GATC's advanced AI platformpredictsoutcomes of early-stage drug candidateswith true positive rate of 86% and true negative rate of 91%,potentially saving billions in lost drug development costs andsignificantly decreasing risk for drug R&D.
IRVINE,Calif., May 16, 2024 /PRNewswire/ -- GATC HealthCorp, a technology company advancing drug discovery and diseaseprediction using artificial intelligence (AI), hassuccessfullycompletedtwo external AI platformvalidation tests in collaboration with a pharmaceutical science labat University of California, Irvine's(UCI). UCI specifically designedthe teststoindependently verify the performance of GATC Health's AI's primarydrug screening capabilities and provide unique and detailedinsights into drug success risks. The successful outcome of thetests mark a significant milestone in the advancement of AI in drugdiscovery.
The results provide further validation of the ability of GATC'sAI platform to effectively measure safety, efficacy, and off-targeteffects in early-stage drug candidates, which are key indicators ofsuccessful phase 1 and phase 2 clinical trials. The studyconfirmed, and in some cases exceeded, GATC's own internalretrospective double-blinded analysis completed in September 2023, which successfully demonstrated atrue positive rate of 86% and a true negative rate of 84%. Thisinternal study analyzed over 14,000 compounds with known outcomesacross hundreds of disease states.
"GATC's ability to predict and measure the likelihood of apotential drug successfully treating a specific disease target andalso whether that drug candidate has safety risks will providepharmaceutical companies and investors with a break-through toolfor making billion-dollar decisions," said Dr. Tomas Philipson, former Acting Chairman of theWhite House Council of Economic Advisers and former senior economicadvisor to the Commissioner of the Food and Drug Administration.Dr. Philipson also serves as an advisor to GATC Health.
The company's AI screening process comprises three steps,collectively aimed at predicting and enhancing the efficiency andsafety of drug discovery:
Safety Screening: Leveraging AI predictions to screen for toxic,or other negative activation on biological targets, this step iscrucial in assessing the safety and potential side effects of adrug molecule.
Efficacy Screening: AI predictions are employed to screen forpositive activation on intended and unintended targets using acombination of simulation and reverse docking AI on broadbiological targets, playing a key role in assessing the efficacy ofa drug molecule, along with a secondary evaluation of sideeffects.
Optimized Screening: Post-initial screening steps, predictionsby the AI are made after the GATC platform and its team haveacquired knowledge about the molecules being researched. Additionaloptimizations lead to results that often outperform blind, verifiedoutcomes from UCI, as reflected in internal studies on AIperformance.
The external tests administered by UCI rigorously adhered toGATC Health's screening process, presenting molecules and theiractivity known only to the UCI lab. GATC received only thechemistry of these molecules before providing predictions to UCI ona predetermined set of biological targets. It is noteworthy thatthe testing of Optimized Screening was not included in the UCItests.
"By modeling human systems biology and molecular target activityin unique ways, our platform uncovers non-obvious solutions thataccelerate all aspects of drug discovery," said Jayson Uffens, Chief Technical Officer andco-founder of GATC Health. "Having a high degree of confidence inthe predicted human outcomes for known and novel compounds allowsGATC and our partners to make decisions leading to higher qualityand lower risk therapeutics."
Methodology:
Following the delivery of predictions by the GATC platform to UCI,the activation data was shared with GATC as the answer key for thetest. The Initial Screening was performed in two separate testsagainst two sets of AI models in the GATC Platform, resulting inindependently verified test results of 91% for the Specificity Test(true positive) and 86% for the Sensitivity Test (true negative).Data used for this independent study consistedof over 4,600molecules between the two tests.
These successful external tests underscore the reliability ofthe GATC Platform's screening capabilities, affirming its potentialto revolutionize the drug discovery landscape. GATC Health remainscommitted to advancing AI-driven solutions that expedite andoptimize the drug discovery process for the benefit of patientsglobally.
About GATC Health
GATC Health Corp is a technologycompany revolutionizing disease prediction and drug discovery anddevelopment through its transformative AI platform and approach,which de-risks drug pipelines and accelerates new therapies totreat disease with accuracy, efficiency and speed never beforeachieved in medical science. The company's validated andproprietary Multiomics Advanced Technology™ (MAT) platformsimulates human biochemistry's billions of interactions foraccurate and rapid disease prediction, novel target identification,and drug discovery and development. GATC envisions the future ofmedicine now, where health is protected, disease is reversed andevery person's unique biology is treated with precision.
View original content to downloadmultimedia:https://www.prnewswire.com/news-releases/university-of-california-irvine-verifies-gatc-healths-ability-to-predict-drug-efficacy-safety-and-off-target-effects-302147239.html
SOURCE GATC Health Corp
